MAIA Biotechnology Inc Sustainability Reports
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for cancer. Its lead asset, THIO, is an investigational cancer telomere targeting agent in clinical development for patients with telomerase-positive cancer cells.
Sector: Manufacturing
Country: United States
Exchange: NYSE American
FIGI: BBG0113Q7J97
1 reports from 2022 to 2022
Company Profile
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for cancer. Its lead asset, THIO, is an investigational cancer telomere targeting agent in clinical development for patients with telomerase-positive cancer cells.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
